Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

According to the study, Moderna's vaccine was 93% effective at preventing COVID-19 hospitalizations, compared to 88% for the Pfizer vaccine and 71% for Johnson and Johnson's.

Moderna also announced that it has initiated a submission to the FDA for emergency use authorization of the company's Covid-19 vaccine for children ages 6 through 11 years old.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Investors were seemingly buoyed by Moderna's vaccine trial results, with U.S. stock futures on Monday pointing to a strong opening. Dow futures were up 476 points, or 1.6%, before the start of ...

Moderna will keep its COVID vaccine on the market at no cost to consumers, even after the federal government stops paying for it, the company announced Wednesday. "Everyone in the United States ...

A second coronavirus vaccine has now joined the fight against COVID-19 in the United States. On December 18, the U.S. Food and Drug Administration authorized Moderna’s vaccine for emergency ...

Kennedy Jr. canceled nearly half a billion dollars’ worth of grants and contracts for mRNA-vaccine research.With Kennedy leading HHS, this about-face is easy to parse as yet another anti-vaccine move.